Skip to content

Rafael Holdings, Inc. RFL Investments and Cash

Investments and Cash at other companies

NOD
NI HoldingsNODK
$374.91M-6.0%
RLI logo
RLIRLI
$4.89B+16.3%
Financial Institutions logo
Financial InstitutionsFISI
$66.94M+1.9%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$496M+33.0%
RFL
Rafael Holdings, Inc.RFL
$1.5M0.0%
Everest Group logo
Everest GroupEG
$45.02B+5.6%

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+189%
P/S174×+93.5×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentsAndCash.

The official record: Rafael Holdings, Inc.’s 10-K, filed October 29, 2025, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s investments and cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s investments and cash?
Rafael Holdings, Inc. (RFL) reported investments and cash of $1.5M in Q2 2025.
How has Rafael Holdings, Inc.'s investments and cash changed year-over-year?
Rafael Holdings, Inc.'s investments and cash decreased by 0.0% year-over-year, from $1.5M to $1.5M.
What does investments and cash mean?
This metric represents the aggregate value of cash, cash equivalents, and long-term investment holdings held by the company that are not intended for immediate operational use. It serves as a measure of the company's liquidity position and its capacity to fund long-term strategic initiatives or research and development projects. For a clinical-stage firm, this balance is critical for assessing the runway available to support ongoing drug development programs.